ER
RARE icon

Enlightenment Research’s Ultragenyx Pharmaceutical RARE Stock Holding History

Enlightenment Research’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$4K – 522
2018
Q4 		$4K Buy
+100
New +$5.46K 0.01% 721

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Enlightenment Research's RARE Position: Q1 2019 in Review

Enlightenment Research sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2019, closing a stake of 100 shares — an estimated $4K sold.

Enlightenment Research first reported a position in RARE in Q4 2018 and held it in 1 quarter. The position peaked at $4K in Q4 2018. 176 funds tracked by Wall St. Rank hold RARE as of Q1 2019.

  • Enlightenment Research reported no remaining Ultragenyx Pharmaceutical position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 100 Ultragenyx Pharmaceutical shares in Q1 2019, an estimated $4K.
  • Enlightenment Research first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Ultragenyx Pharmaceutical position peaked at $4K in Q4 2018.
  • 176 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.